Ambrx is a clinical-stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop next-generation antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system. Ambrx is advancing a focused portfolio of clinical and preclinical programs designed to optimize efficacy and safety in multiple cancer indications, including ARX517, its proprietary ADC targeting the prostate-specific membrane antigen (PSMA) and ARX788, its proprietary ADC targeting HER2. In addition, Ambrx has preclinical and clinical collaborations with multiple partners on drug candidates generated using Ambrx technology. Ambrx was spun out of The Scripps Research Institute in 2003 and has several other product candidates involving ADCs and other aspects of Ambrx’s protein engineering technology. For more information, please visit www.ambrx.com. Ambrx routinely posts information that may be important to investors on its website.
Company profile
Ticker
AMAM
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
New Ambrx Biopharma Inc.
SEC CIK
AMAM stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
18 Mar 24
8-K
Departure of Directors or Certain Officers
12 Mar 24
EFFECT
Notice of effectiveness
11 Mar 24
S-8 POS
Registration of securities for employees (post-effective amendment)
8 Mar 24
S-8 POS
Registration of securities for employees (post-effective amendment)
8 Mar 24
S-8 POS
Registration of securities for employees (post-effective amendment)
8 Mar 24
S-8 POS
Registration of securities for employees (post-effective amendment)
8 Mar 24
S-8 POS
Registration of securities for employees (post-effective amendment)
8 Mar 24
POS AM
Prospectus update (post-effective amendment)
7 Mar 24
25-NSE/A
Exchange delisting (amended)
7 Mar 24
Latest ownership filings
4
Kate Hermans
7 Mar 24
4
Janet Loesberg
7 Mar 24
4
Daniel J. O'Connor
7 Mar 24
4
Stephen C. Glover
7 Mar 24
4
Andrew Aromando
7 Mar 24
4
Sonja Nelson
7 Mar 24
4
MARGARET DALESANDRO
7 Mar 24
4
PAUL V MAIER
7 Mar 24
SC 13G/A
Venrock Healthcare Capital Partners III, L.P.
14 Feb 24
SC 13G/A
D. E. SHAW & CO, L.P.
14 Feb 24
Financial summary
Quarter (USD) | Sep 23 | |
---|---|---|
Revenue | ||
Cost of revenue | ||
Operating income | ||
Operating margin | ||
Net income | ||
Net profit margin | ||
Cash on hand | ||
Change in cash | ||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | |||
---|---|---|---|---|---|---|
Cash on hand (at last report) | 225.93 mm | 225.93 mm | ||||
Cash burn (monthly) | 8.54 mm | 233.67 k | ||||
Cash used (since last report) | 59.17 mm | 1.62 mm | ||||
Cash remaining | 166.75 mm | 224.31 mm | ||||
Runway (months of cash) | 19.5 | 959.9 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
7 Mar 24 | Dalesandro Margaret | RSU Common Stock | Sale back to company | Dispose D | No | No | 0 | 10,119 | 0.00 | 0 |
7 Mar 24 | Dalesandro Margaret | RSU Common Stock | Sale back to company | Dispose D | No | No | 0 | 17,857 | 0.00 | 0 |
7 Mar 24 | Andrew Aromando | Option to Purchase Common Stock Common Stock | Sale back to company | Dispose D | No | No | 16.66 | 55,570 | 925.80 k | 0 |
7 Mar 24 | Andrew Aromando | Option to Purchase Common Stock Common Stock | Sale back to company | Dispose D | No | No | 9.66 | 371,428 | 3.59 mm | 0 |
7 Mar 24 | Andrew Aromando | RSU Common Stock | Sale back to company | Dispose D | No | No | 0 | 100,000 | 0.00 | 0 |
7 Mar 24 | O'Connor Daniel J. | Common Stock | Sale back to company | Dispose D | No | No | 0 | 48,202 | 0.00 | 0 |
7 Mar 24 | O'Connor Daniel J. | Option to Purchase Common Stock Common Stock | Sale back to company | Dispose D | No | No | 16.66 | 173,785 | 2.90 mm | 0 |
7 Mar 24 | O'Connor Daniel J. | Option to Purchase Common Stock Common Stock | Sale back to company | Dispose D | No | No | 0.91 | 772,857 | 703.30 k | 0 |
7 Mar 24 | O'Connor Daniel J. | RSU Common Stock | Sale back to company | Dispose D | No | No | 0 | 750,000 | 0.00 | 0 |
7 Mar 24 | O'Connor Daniel J. | RSU Common Stock | Sale back to company | Dispose D | No | No | 0 | 294,643 | 0.00 | 0 |
Press releases
Ambrx Shareholders Approve Acquisition by Johnson & Johnson
6 Mar 24
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates AMAM, JNPR, INBX, RYZB
12 Feb 24
Kuehn Law Encourages AMAM, DOOR, CBAY, and WISH Investors to Contact Law Firm
12 Feb 24
AMBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Ambrx Biopharma, Inc. - AMAM
10 Feb 24
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates AMAM, HARP, JNPR, TGAN
10 Feb 24